| Dr Mark Joseph Eanes, MD | |
|
2310 N Patterson St, Suite B, Valdosta, GA 31602-2568 | |
| (229) 247-2020 | |
| (229) 247-5600 |
| Full Name | Dr Mark Joseph Eanes |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 42 Years |
| Location | 2310 N Patterson St, Valdosta, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205947496 | NPI | - | NPPES |
| 00330316A | Medicaid | GA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 025970 (Georgia) | Primary |
| Entity Name | South Health District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295899524 PECOS PAC ID: 0648255018 Enrollment ID: O20040621000728 |
News Archive
The U.S. Food and Drug Administration today approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia who have a specific genetic mutation called FLT3, in combination with chemotherapy.
The results of a randomized controlled trial presented today at the Annual European Congress of Rheumatology demonstrate high levels of treatment success in approximately two thirds of patients despite tapered glucocorticoid discontinuation, while a small loss of disease control was observed at the total study population level.
InNexus Biotechnology Inc. has announced the United States Food & Drug Administration (FDA) has completed its comprehensive review of the development plans for InNexus' lead preclinical candidate, DXL625 (CD20) for the prospective treatment of Non-Hodgkin's Lymphoma (NHL) and/or Chronic Lymphocytic Leukemia (CLL).
To help healthcare providers image patients faster and more comfortably, Toshiba America Medical Systems, Inc. is introducing enhancements to its Vantage TitanTM MR product line. The new technologies improve workflow, image quality and patient comfort.
The era of one-size-fits-all medicine will eventually be history; after all it is no news that drugs and treatments do not work the same for everyone. For patients with nonsmall cell lung cancer, a lung cancer that kills approximately 1 million people annually, the treatment currently available is basically the same for all patients, despite the fact that some patients may respond to treatment while others may not.
› Verified 2 days ago
| Entity Name | Southern Eye Center, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316020043 PECOS PAC ID: 3779602057 Enrollment ID: O20120229000755 |
News Archive
The U.S. Food and Drug Administration today approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia who have a specific genetic mutation called FLT3, in combination with chemotherapy.
The results of a randomized controlled trial presented today at the Annual European Congress of Rheumatology demonstrate high levels of treatment success in approximately two thirds of patients despite tapered glucocorticoid discontinuation, while a small loss of disease control was observed at the total study population level.
InNexus Biotechnology Inc. has announced the United States Food & Drug Administration (FDA) has completed its comprehensive review of the development plans for InNexus' lead preclinical candidate, DXL625 (CD20) for the prospective treatment of Non-Hodgkin's Lymphoma (NHL) and/or Chronic Lymphocytic Leukemia (CLL).
To help healthcare providers image patients faster and more comfortably, Toshiba America Medical Systems, Inc. is introducing enhancements to its Vantage TitanTM MR product line. The new technologies improve workflow, image quality and patient comfort.
The era of one-size-fits-all medicine will eventually be history; after all it is no news that drugs and treatments do not work the same for everyone. For patients with nonsmall cell lung cancer, a lung cancer that kills approximately 1 million people annually, the treatment currently available is basically the same for all patients, despite the fact that some patients may respond to treatment while others may not.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mark Joseph Eanes, MD 2310 N Patterson St, Suite B, Valdosta, GA 31602-2568 Ph: (229) 247-2020 | Dr Mark Joseph Eanes, MD 2310 N Patterson St, Suite B, Valdosta, GA 31602-2568 Ph: (229) 247-2020 |
News Archive
The U.S. Food and Drug Administration today approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia who have a specific genetic mutation called FLT3, in combination with chemotherapy.
The results of a randomized controlled trial presented today at the Annual European Congress of Rheumatology demonstrate high levels of treatment success in approximately two thirds of patients despite tapered glucocorticoid discontinuation, while a small loss of disease control was observed at the total study population level.
InNexus Biotechnology Inc. has announced the United States Food & Drug Administration (FDA) has completed its comprehensive review of the development plans for InNexus' lead preclinical candidate, DXL625 (CD20) for the prospective treatment of Non-Hodgkin's Lymphoma (NHL) and/or Chronic Lymphocytic Leukemia (CLL).
To help healthcare providers image patients faster and more comfortably, Toshiba America Medical Systems, Inc. is introducing enhancements to its Vantage TitanTM MR product line. The new technologies improve workflow, image quality and patient comfort.
The era of one-size-fits-all medicine will eventually be history; after all it is no news that drugs and treatments do not work the same for everyone. For patients with nonsmall cell lung cancer, a lung cancer that kills approximately 1 million people annually, the treatment currently available is basically the same for all patients, despite the fact that some patients may respond to treatment while others may not.
› Verified 2 days ago
Dr. Anthony P Johnson, M.D. Ophthalmology Medicare: Medicare Enrolled Practice Location: 4120 N Valdosta Rd Ste A, Valdosta, GA 31602 Phone: 229-244-2068 Fax: 229-244-2850 | |
James Garrett Webster, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 4120 N Valdosta Rd Ste A, Valdosta, GA 31602 Phone: 229-244-2068 Fax: 229-244-2850 | |
Ben H Moye, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 3024 N Patterson St, Valdosta, GA 31602 Phone: 229-247-4114 Fax: 229-245-9042 | |
Dr. Steven Thomas Greenhaw, M D Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2704 N Oak St, Valdosta, GA 31602 Phone: 229-245-7070 Fax: 229-245-9005 | |
Dr. Donald John Mirate, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 2707 N Forrest St, Valdosta, GA 31602 Phone: 229-244-8799 Fax: 229-247-2609 | |
Dr. Albert Gonzalez-acevedo, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3024 N Patterson St, Valdosta, GA 31602 Phone: 229-247-4114 Fax: 229-245-9042 |